Background/Introduction: Chronic kidney disease (CKD) is a risk factor for contrast induced acute kidney injury (CI-AKI). Contrast angiography in CKD patients is a common procedure. Creatinine is a delayed marker of CI-AKI and delays diagnosis which results in significant morbidity and mortality. Aim: Early diagnosis of CI-AKI requires validated novel biomarkers. Design: A prospective observation study of 301 consecutive CKD patients undergoing coronary angiography was performed. Methods: Samples for plasma neutrophil gelatinase-associated lipocalin (NGAL), serum liver fatty acid-binding protein (L-FABP), serum kidney injury marker 1, serum interleukin 18 and serum creatinine were taken at 0, 1, 2, 4, 6 and 48 h postcontrast. Urinary NGAL and urinary cystatin C were collected at 0, 6 and 48 h. Incidence of major adverse clinical events (MACE) was recorded at 1 year. CI-AKI was defined as an absolute delta rise in creatinine of !26.5 mmol/l or a 50% relative rise from baseline at 48 h following contrast. Results: CI-AKI occurred in 28 (9.3%) patients. Plasma NGAL was most predictive of CI-AKI at 6 h. L-FABP performed best at 4 h. A combination of Mehran score > 10, 4 h L-FABP and 6 h NGAL improved specificity to 96.7%. MACE was statistically higher at 1 year in CI-AKI patients (25.0 vs. 6.2% in non-CI-AKI patients). Discussion/Conclusion: Mehran risk score, 4 h serum L-FAPB and 6 h plasma NGAL performed best at early CI-AKI prediction. CI-AKI patients were four times more likely to develop MACE and had a trebling of mortality risk at 1 year.
Introduction

Contrast induced acute kidney injury
Acute kidney injury (AKI) is both a serious and common condition. The incidence of AKI varies among hospitalized patients but ranges from 5 to 20% in published studies. [1] [2] [3] Despite recent advances, inhospital morbidity and mortality remains dismally high. 4 Serum creatinine is the most widely used biomarker to detect AKI but exhibits delayed accumulation following renal injury, a characteristic intrinsically limiting its utility as an early marker of AKI. In the majority of published studies, contrast induced AKI (CI-AKI) has been defined by a 25% creatinine rise within 48 h. 6 In 2011, the kidney disease improving global outcomes (KDIGO) practice guidelines incorporated the AKI network definition and in so doing promoted a clinically meaningful and globally accepted standard. 7 Previous AKI definitions, e.g. a relative 50 or 25% rise in creatinine rise at 48 h, failed to highlight the importance of modest absolute creatinine rises. To reflect the considerable mortality risk associated with modest creatinine elevations a delta rise of !26.5 mmol/l in or a 50% rise within 48 h is accepted as the most current definition of AKI. 7 CI-AKI is an iatrogenic form of AKI consequent to iodinated contrast exposure. 6 Contrast induces intra-renal vasoconstriction of the afferent glomerular arteriole reducing glomerular capillary pressure and net filtration pressure. 8 
Rates of CI-AKI
To illustrate the effect of chronic kidney disease (CKD) a study of over 7000 consecutive percutaneous coronary intervention (PCI) patients (CI-AKI defined as !25% increase from baseline serum creatinine at 48 h) reported a CI- 
Risk factors for AKI and CI-AKI
The strongest risk factor for AKI development is the presence of pre-existent CKD. Other independent risk factors which form part of the internationally recognized Mehran AKI risk score include increasing age, diabetic nephropathy, peripheral vascular disease, advanced cardiac failure and the use of non-iso-osmolar contrast agents, 12, 13 Figure 1 . Modern day contrast agents are benzoic acid derivatives containing three iodine atoms per benzene ring. 14 Initial contrast agents were ionic resulting in high osmolalities and were classified as high-osmolar contrast media. During the 1980s formulations were introduced in which the iodine containing benzene ring was non-ionic resulting in a marked reduction in osmolality. These second line agents were known as low-osmolar contrast media. 14 A further reduction in osmolality has been achieved with iso-osmolar contrast media which has been associated with a lower risk of CI-AKI in many clinical trials and meta-analysis.
15-19
Novel biomarkers
Plasma neutrophil gelatinase-associated lipocalin (NGAL), serum liver fatty acid-binding protein (L-FABP), serum kidney injury marker 1 (KIM-1), serum interleukin 18 (IL-18) and cystatin C (CysC) are produced mainly from the proximal tubule, Figure 2 . Several studies have proposed these as early biomarkers of AKI in a variety of studies. These studies are discussed in the Discussion.
Hypothesis
Our hypothesis is that novel biomarkers of CI-AKI produced mainly from the proximal tubule can predict CI-AKI much sooner than is currently feasible with creatinine and that biomarker rises at index angiography are associated with adverse outcomes at 1 year. 
Materials and methods
Setting and participants
A prospective cohort study in a single cardiology centre in UK was carried out. Patients at high risk of CI-AKI, evidenced by the presence of CKD (baseline GFR 60 mls/min as defined by modification of diet in renal disease criteria) were identified prior to elective cardiac catheterization. Patients with recent myocardial infarction, hospitalization or heart failure (within 6 weeks of recruitment) were excluded.
Recruitment
We screened 2519 patients over a 2 year period. Of these patients, 321 (12.7%) had a GFR < 60 mls/min. Of these 321 patients, 20 were excluded resulting in a final cohort of 301 patients, Figure 3 . Of note, 32 (10.6%) of patients undergoing contrast angiography has a GFR < 30 mls/min. 
Measurements
Samples for plasma NGAL, serum L-FABP, serum KIM-1, serum IL-18 and serum creatinine were collected via venipuncture at 0, 1, 2, 4, 6 and 48 h post-contrast. As patients were not catheterized, the frequency of urinary sampling for urinary NGAL and urinary CysC was 0, 6 and 48 h. Samples were centrifuged within 30 min of sampling at 3800Â for 5 min. Following centrifuge, the supernatant fluid was transferred into anonymously coded cryotubes and immediately frozen at À80 C. All biomarker measurements were performed in one core laboratory (Randox Laboratories Ltd, Crumlin, Northern Ireland) on blinded samples. Directly prior to biomarker measurement and biochip analysis, samples were thawed in one freeze-thaw cycle. All patient time points were measured within the same biochip run. An 'Evidence Investigator' analyser (Randox Laboratories Ltd) with biochips (Randox Laboratories Ltd) was used for measurement of biomarkers. Urinary NGAL, urinary CysC and serum creatinine were measured using Randox kits on a RX Daytona analyser (Randox Laboratories Ltd).
Statistical analysis
Categorical variables are presented as total number (n) and percentage (%). Continuous variables are presented as mean and standard deviation (SD). Categorical variables were compared using Chi squared test. Continuous variables were compared using independent student t-test when parametric (normally distributed) and Mann-Whitney U test when non-parametric (not normally distributed). Shapiro-Wilk test was used to assess for normality. Statistical significance was considered if P < 0.05. Receiver operating characteristic analysis using area under curve (AUC) was used to assess the diagnostic accuracy of biomarkers by displaying true-positive rates (sensitivity) versus false-positive rates (1-specificity). Data was analysed using SPSS version 22. 20 Logistic regression analysis was applied. For analysis of NGAL and L-FABP an upper reference limit (URL) of 964 ng/ml for NGAL and 12.1 ng/ml for L-FABP was used (as per Randox Laboratories Ltd biochip reference range).
We assessed patients for secondary endpoints of major adverse clinical events (MACE) at 1 year which included acute myocardial infarction, heart failure hospitalization, stroke and death.
Results
Baseline demographics
Of the 301 recruited patients, 28 (9.3%) developed CI-AKI. Twenty (71.4%) of the CI-AKI patients were male compared with 150 (55.0%) of non-CI-AKI patients (P ¼ 0.102). Baseline demographics of CI-AKI versus non-CI-AKI patients are shown in Table 1 . Patients who developed CI-AKI were more likely to have a higher creatinine, lower GFR, higher Mehran score, receive more iodinated contrast and be anaemic. Many of these factors feature in the Mehran risk score.
Biomarkers
The URL of the NGAL biochip is 964 ng/ml (Randox Laboratories Ltd) is Median plasma NGAL levels were statistically significantly higher in CI-AKI patients at all time points, even prior to contrast administration. NGAL performed best at 6 h post-contrast with median levels of 1337 ng/ml in the CI-AKI group compared with 931 ng/ml in the non-CI-AKI group, AUC 0.71, specificity 96.1%, negative predictive value (NPV) 96.1% and relative risk (RR) 2.98 (Table 2, Figure 4) .
The URL of the LFABP biochip is 12.1 ng/ml (Randox Laboratories Ltd). Median serum L-FABP levels statistically performed best at 4 h post-contrast with median levels of 10.7 ng/ ml in the CI-AKI group compared 6.2 ng/ml in the non-CI-AKI patients, although this was less significant than for NGAL (Table 2) . CI-AKI patients had significantly higher levels urinary NGAL, although only at 48 h post-contrast. Median urinary NGAL levels were 799 ng/ml in the CI-AKI group compared with 392 ng/ml in the non-CI-AKI group, AUC 0.63, P ¼ 0.008. However, with a 48 h delay this would not be beneficial over creatinine. This likely reflects filtration of serum NGAL.
Median levels of urinary CysC at each time point remained <0.4 mg/l (the lowest detectable value for CysC) and were not useful for CI-AKI prediction.
Median serum KIM-1 levels were not statistically different until 48 h post-contrast. Median KIM-1 was 0.21 ng/ml in the CI-AKI group compared with a median of 0.16 in the non-CI-AKI group, AUC 0.65, P ¼ 0.019. Similarly, to urinary NGAL, with a 48 h delay this would not be beneficial over creatinine.
Serum IL-18 was not statistically significant at predicting CI-AKI at any time point, AUC range 0.40-0.54, P > 0.05.
Mehran score
Median Mehran risk score was 11 in the CI-AKI group and 8 in the non-CI-AKI group, with a score ! 10 achieving an AUC of 0.65, P ¼ 0.006, sensitivity 64%, specificity 62%, positive predictive value 10%, NPV 94%, RR 2.63 and odds ratio (OR) 2.9, Table 3 .
Logistic regression identified diabetes, CKD stage and GFR most associated with CI-AKI (P < 0.05).
Combination approach
From the results presented, plasma NGAL, serum L-FABP and Mehran risk score were the best predictors of CI-AKI. A combination approach was adopted to assess different biomarkers and time points showing a 4 h L-FABP combined with Mehran score had the highest OR of 9.45 and highest RR of 5.99, AUC 0.65, P < 0.001, Table 4 . A 6 h NGAL combined with 4 h L-FABP and Mehran score had the highest specificity at 96.4%, OR 6.27, Table 4 .
MACE
At 1 year, MACE was observed in 7 (25.0%) CI-AKI patients versus 17 (8.3%) non-CI-AKI patients, P < 0.001. Mortality at 1 year was 3 (10.7%) in the CI-AKI group compared with 8 (3.3%) in the non-CI-AKI group, P ¼ 0.037, Figure 5 .
Discussion
Novel renal CI-AKI biomarkers
NGAL is a 25 kDa protease-resistant polypeptide that was initially identified bound to gelatinase in specific granules of the neutrophil. 21 Plasma NGAL accumulates in renal cortical tubules, blood and urine following nephrotoxic and ischaemic injury. 21 A recent publication by Quintavalle et al. 22 indicated that serum and urine NGAL levels at 6 h may help exclude development of CI-AKI (serum NGAL sensitivity 74%, specificity 52%, AUC 0.62, P ¼ 0.045 and urine NGAL sensitivity of 75%, specificity 52%, AUC 0.61, P ¼ 0.001). Several other studies have demonstrated NGAL rises in CI-AKI cases as soon as 2-4 h post-angiography. [23] [24] [25] Another biomarker under preliminary investigation is L-FABP, solely localized to the cytoplasmic region of the proximal tubular cells it selectively binds to intracellular free unsaturated fatty acids during hypoxic tissue injury. 26 Only a few studies have been reported in the setting of contrast induced renal disease but data suggest L-FABP rises between 4 and 24 h post-contrast in CI-AKI cases. 23, [27] [28] [29] Other established AKI markers, KIM-1, CysC and IL-18 have not been studied in detail but available data indicates they appear to rise only after 24-48 h following contrast 25, 27, [30] [31] [32] [33] and as such offer no advantage over creatinine measurement. Recent studies have assessed intravenous contrast in patients undergoing radiological procedures. A study by McDonald et al. assessed patients undergoing computed tomography scans of thorax, abdomen and pelvis. This concluded that there was no significant difference in AKI incidence between contrast enhanced and non-contrast enhanced studies in the same patient during the study period. 34 A further study by McDonald et al. 35 concluded that contrast was not associated with excess risk of AKI, dialysis or death. However, this trial only had a follow-up period of 30 days which may explain the lack of a significant difference. Another study by Hemmett et al. 36 also concluded that incidence of AKI was not different between those who received contrast and those who didn't receive contrast. However, the dose of iodinated contrast given during PCI will be significantly greater than the volume used for radiological procedures.
In this study, CI-AKI was significantly associated with increasing age, lower GFR, higher creatinine, Mehran Bold, statistically significant (P < 0.05). CI-AKI, contrast induced acute kidney injury; IHD, ischaemia heart disease; PCI, percutaneous coronary intervention; DM, diabetes mellitus; GFR, glomerular filtration rate and SD, standard deviation. Table 1 highlights the baseline characteristics of CI-AKI and non-CI-AKI patient, showing significant differences between the two groups.
score, higher volumes of contrast, anaemia, diabetes and administration of intravenous fluids. Plasma NGAL performed well for CI-AKI prediction. Even at baseline (prior to administration of contrast), median plasma NGAL was noted to be significantly higher in those who developed CI-AKI compared with non-CI-AKI. This has significant importance in real world clinical practice as a predictive tool prior to undergoing iodinated contrast procedures. The best predictive time point for plasma NGAL (>964 ng/dl) was the 6 h sample. Translating these results to clinical practice (i) if plasma NGAL is negative at 6 h, patients have <4% of CI-AKI and so could be safely discharged from hospital care with suitable CI-AKI advice and (ii) only the highest risk patients would be appropriately admitted to acute hospital beds.
The most predictive time point for L-FABP was at 4 h (>12.1 ng/ml) when it demonstrated a sensitivity 42.3%, specificity 90.2%, P ¼ 0.001, AUC 0.69. These results indicate serum L-FABP could be applied as a pre-procedural screening tool (on the morning of the procedure or at a pre-assessment clinic) or in combination with plasma NGAL.
Urinary NGAL performed less impressively than plasma NGAL. Urinary CysC was not found to be useful for predicting CI-AKI at any time point. KIM-1 performed similarly to urine NGAL and as such it not a useful early CI-AKI predictor. IL-18 performed poorly at all recorded time points. The median Mehran score in those who developed CI-AKI was 11 compared with 8 in the non-CI-AKI group, AUC 0.65, P ¼ 0.006. As a CI-AKI 'rule out' policy, combining a Mehran risk score > 10, serum L-FABP > 12.1 ng/ml at 4 h and plasma NGAL > 964 ng/dl at 6 h achieved an AUC of 0.57, P ¼ 0.002, sensitivity 19%, specificity 96.4%, NPV 88.8% and OR 6.27.
MACE was statistically higher at 1 year in CI-AKI patients, 25.0 versus 6.2% in non-CI-AKI patients. Similarly, mortality was significantly higher in CI-AKI patients at 1 year, 10.7 versus 3.3%.
This study has allowed the authors to develop a new proposed pathway using Mehran scores and biomarkers to help decision making which should reduce morbidity and mortality, Figure 6 . It is proposed that this pathway will be used in all patients undergoing contrast angiography with a GFR < 60 mls/ min. All staff are currently undergoing training to implement this pathway in our centre. Similarly, we are in consultation with radiology colleagues regarding implementing AKI safety measures for patients undergoing all contrast procedures.
Limitations
This was performed in a single centre only a small number (9.3%) developed CI-AKI (although this is in keeping with other published literature).
9, 10 Time points were limited to an extent as patients were stable out-patients routinely discharged at 6 h. This was particularly problematic with urine sampling. As we have demonstrated, the time course release of urinary NGAL was between 6 and 48 h in CI-AKI patients however a lack of sampling failed to accurately highlight this. Although specificity, NPVs and P values were impressive for 6 h NGAL and 4 h L-FABP, the AUC for biomarkers was disappointing. This is likely as a consequence of the balance between of sensitivity and specificity of novel biomarkers.
Strengths
There are notably strengths to this study. Most previously published articles in this field have small numbers and few time points. Each of our 301 patients had 4 plasma/serum biomarkers taken at each of six time points and 2 urinary biomarkers taken at each of three time points. This allowed accurate time course release data from each biomarker in both CI-AKI and non-CI-AKI patients. Multiple biomarkers were analysed from the same plasma/serum samples providing strong internal validity to our data. Sensit, sensitivity; Specif, specificity, PPV, positive predictive value; NPV, negative predictive value; RR, relative risk; OR, odds ratio and IQR, interquartile range. Table 2 compares NGAL/L-FABP time points with 6 h NGAL and 4 h L-FABP performing best. 
Conclusion
As a 'rule out' strategy, plasma NGAL combined with Mehran score had the highest NPV of 96.1% and highest sensitivity of 75% which is clinically useful for safe early discharge. Combining a Mehran risk score > 10, serum L-FABP > 12.1 ng/ml at 4 h and plasma NGAL > 964 ng/dl at 6 h achieved an AUC of 0.57, P ¼ 0.002, sensitivity 19%, specificity 96.4%, NPV 88.8% and OR 6.27. MACE and mortality was significantly higher in patients who developed CI-AKI at 1 year. Our proposed patient pathway utilizing serum NGAL and plasma L-FABP in combination with a Mehran risk score has the potential to detect and/or rule out CI-AKI much earlier than is currently feasible. This would enable more timely therapeutic intervention to reduce patient morbidity and mortality in affected cases or facilitate safe early discharge when lowest risk.
The implications of our results, translated to the design of safer elective coronary intervention services able to more efficiently manage the increasing volume of contrast studies, should be a key health priority for providers of cardiac and renal services.
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